The content on this site is intended for healthcare professionals only
Dr Chiara Braconi speaks to ecancer about genomic testing in biliary tract cancers. She initially talks about the three subtypes of cholangiocarcinoma and gallbladder cancer.
Dr Braconi then expands on why, when, and how to test BTC patients.
She talks about the limitations of clinical application in BTC and future considerations.
Dr Braconi also compares single-gene analysis to multi-gene analysis. She concludes by talking about liquid biopsies for BTC.
Aspirin in stage III colorectal cancer shows no significant DFS benefit but favourable safety
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Durvalumab, gemcitabine and cisplatin continue to show clinically meaningful long-term survival in biliary tract cancer patients
Immunotherapy significantly increases the number of patients free from bowel cancer
ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma
EAU 2024: Bladder cancer latest
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
